I7409
Monoclonal Anti-Interleukin-1α propeptide antibody produced in mouse
clone 409405, purified immunoglobulin, lyophilized powder
Synonym(s):
Anti-IL1, Anti-IL1A
biological source
mouse
Quality Level
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
409405, monoclonal
form
lyophilized powder
species reactivity
human
technique(s)
western blot: 1-2 μg/mL
isotype
IgG2b
UniProt accession no.
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... IL1A(3552)
General description
Interleukins are proinflammatory cytokines produced on cell injury or trauma. There are two closely related types of interleukins produced by the cell, IL-1α and IL-1β that are produced by the activation of NF-κ B transcription factor in response to bacterial infection or LPS. Both IL-1α and IL-1β exert their cellular effects by signalling through IL-1 receptor type 1. The IL-1α precursor produced initially is cleaved by calpain to produce a 16 kDa propeptide and 17 kDa mature protein. A variety of cells such as macrophages, epithelial cells, fibroblasts, keratinocytes, monocytes and dendritic cells secrete IL-1α. Both IL-1α and IL-1β are important in acquired immunity, inflammation, response to infection and production of matrix metalloproteinases (MMPs). The propeptide has nuclear localization sequence that enables it to shuttle to nucleus and activate transcription of target genes. The effects of IL-1α are mediated by activation of NF-κB, JNK and MAPK pathways that activated the genes in response to infection and inflammation.Overproduction of IL-1α has been implicated in inflammatory disorders like rheumatoid arthritis and periodontitis
Monoclonal Anti-Interleukin-1a propeptide recognizes human Interleukin-1α propeptide. It does not cross-react with mature forms of mouse IL-1α or rabbit IL-1α.
Monoclonal Anti-Interleukin-1a propeptide recognizes human Interleukin-1α propeptide. It does not cross-react with mature forms of mouse IL-1α or rabbit IL-1α.
Immunogen
purified, E. coli-derived recombinant human interleukin-1α propeptide (aa 1-112).
Application
Anti-interleukin 1α antibody is suitable for immunoblotting at a working concentration of 1-2 μg/ml.
Physical form
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline with 5% trehalose.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class
13 - Non Combustible Solids
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Interleukin-1, inflammasomes, autoinflammation and the skin
Contassot E et al
Swiss Medical Weekly, 142, w13590-w13590 (2010)
Interleukin-1 (IL-1) pathway
Weber A et al
Science Signaling, 3, p-p (2010)
S Z Ben-Sasson et al.
Cytokine, 56(1), 122-125 (2011-08-17)
IL-1 strikingly enhances antigen-driven responses of CD4 and CD8 T cells. It is substantially more effective than LPS and when added to a priming regime of antigen plus LPS, it strikingly enhances cell expansion. The effect is mediated by direct
J Novak et al.
Scientific reports, 10(1), 6995-6995 (2020-04-26)
Interleukin-1α (IL-1α) is a dual-function proinflammatory mediator. In addition to its role in the canonical IL-1 signaling pathway, which employs membrane-bound receptors, a growing body of evidence shows that IL-1α has some additional intracellular functions. We identified the interaction of
Charles A Dinarello
Current opinion in pharmacology, 4(4), 378-385 (2004-07-15)
All biological agents currently used for reducing TNFalpha activity in disease are neutralization strategies; however, there are several strategies for reducing interleukin (IL)-1 activities: the IL-1 receptor antagonist (IL-1Ra), anti-IL-1beta monoclonal antibodies, the IL-1 Trap, IL-1 receptor type I antibodies
Related Content
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service